Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-96

Or another pathway to consider after LC’s updates yesterday. She spoke of expansion trials. ie: more short trials ala Bile Duct Cancer. If IMU identify 3 more untreatable solid tumor types. Particularly metastatisised solid tumors . So these cancers have spread throughout the body, then 3 short 10 person registrational trials will give us 4 FDA marketing approvals.

In the USA doctors can prescribe a FDA approved drug for any indication they see as beneficial for the patient. It’s called OFF-Label. It’s very common. As with OZEMPIC for T2 Diabetes now used OFF label for weight loss. And its sales have skyrocketed.

IMU could conceivably have CF33 in the market within 18 months, As CF33 is the only treatment in the world that can kill metastasised Solid Tumors, the Off-Label sales would skyrocket.

Just so much great information in those 2 videos released yesterday. As the strategy gets unveiled here, it’s becoming obvious the LC is a genius when it comes to trial strategy.

Any Oncologist could also prescribe BLYCINTO in combination with CF33 for their patients. There does not have to be a deal in place between the two companies.

Another example of LC’s brilliant strategy was that she chose BLYCINTO as the Cd19 targeting therapy which voids the issues currently being encountered by currently approved CarT therapies.

Great to see the market turning as observers digest the news of progress. I was out early buying IMU’s and IMUOD’s and IMUOE’s this morning.

Although IMUOE’s are getting scarce’